Navigation Links
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering

OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Stock Offering Click to view news release full screen  

OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering


BOTHELL, WA, and VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced a public offering of 3,174,602 units, with each unit consisting of one share of the Company's common stock and one-half (1/2) of one warrant, at a purchase price of $15.75 per unit for an aggreate offering amount of $50 million. The net proceeds to OncoGenex, after underwriting discounts and commissions and other offering expenses, from the sale of the units are expected to be approximately $46.7 million. The Company intends to use the net proceeds from the offering primarily to advance its product pipeline, including its lead program, custirsen, and OGX-427, which is currently in clinical development as a treatment for prostate cancer and bladder cancer, as well as for general corporate purposes. 

Each whole warrant will be exercisable at any time on or after the date of issuance until the fifth anniversary of the date of issuance at an exercise price of $20. The shares of common stock and warrants are immediately separable and will be issued separately. The offering is expected to close on October 22, 2010, subject to customary closing conditions. 
Stifel Nicolaus Weisel is acting as sole book-running manager and Needham & Company, LLC, Rodman & Renshaw, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.

The offering is being made to purchasers outside of Canada pursuant to an effective shelf registration statement that OncoGenex filed with the Securities and Exchange Commission, or the SEC, on June 26, 2009, as amended on July 13, 2009.  A prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the prospectus relating to these securities may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attention: General Counsel, (415) 364-2500.  Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock and warrants of OncoGenex Pharmaceuticals, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at

More information about OncoGenex is available at OncoGenex' Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' intention to conduct a public offering of common stock and warrants.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks relating to OncoGenex' operations and financial performance and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for second fiscal quarter of 2010 and the preliminary prospectus supplement to be filed with the SEC.  The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
2. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. OncoGenex Reports Second Quarter Financial Results
6. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
Post Your Comments:
(Date:10/8/2015)... ... October 08, 2015 , ... ... fibrosis transmembrane conductance regulator (CFTR) gene and results in dysfunction of the lungs ... accumulates in the lungs. This mucus is very difficult to clear, blocks the ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
(Date:10/7/2015)... ... October 07, 2015 , ... ... will present a public educational seminar on the latest advances in adult stem ... 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square in Southlake, ...
(Date:10/7/2015)... N.J. , Oct. 7, 2015  ContraVir Pharmaceuticals, ... a biopharmaceutical company focused on the development and commercialization ... an underwritten public offering of 5,000,000 shares of its ... shares of the Company,s common stock at a fixed ... of common stock and warrants will be issued separately.  ...
Breaking Biology Technology:
... , Purpose , ... the use of chloramphenicol (CAP) as a veterinary drug for food ... for the identification and quantification of CAP in milk and milk ... many analytical procedures are described in the literature, the presented method ...
... , ... and detailed structural data of highlyknotted spider toxins , ... The primary structure determination ... cLC 492 sequencing system and the QSTAR Pulsar hybrid quadrupole time-of-flight mass spectrometer. ...
... Abstract , The generation of hybrid ... production is a fundamental and well-established technique. However, , ... , has varied little over the years. ... antigens is particularly problematic. We have developed a robust , ...
Cached Biology Technology:
(Date:10/2/2015)... DUBLIN , Oct. 02 2015 ... addition of the "Enforcing the Law Using ... ) has announced the addition of ... report to their offering. --> Research ... addition of the "Enforcing the Law Using ...
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/29/2015)... MILWAUKEE , Sept. 29, 2015  iDAvatars is excited ... partners to introduce its product to market. The official announcement was ... Cognitive Economy event in San Francisco ... Avatar platform powered by IBM Watson. "It is ... the first 100 companies to bring to market the cognitive ...
Breaking Biology News(10 mins):
... 16 issue of the journal Cell Host & ... this immune response in mice infected with lymphocytic choriomeningitis ... of drug treatments for immunosuppressive diseases in humans. ... of the interferon response in vivo," says the paper,s ...
... at the University of Delaware have discovered that when the ... it can send out an S.O.S. to the roots for ... that brings beneficial bacteria to the rescue. The finding ... of passing pathogens--and sheds new light on a sophisticated signaling ...
... TALLAHASSEE, Fla. -- The discovery of a protein involved ... a researcher at the Florida State University College of ... Institutes of Health. Branko Stefanovic, associate professor in ... Medicine, hopes his discovery could lead to treatment methods ...
Cached Biology News:
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
... Kit is one of the most ... of RNA in solution. The ... than absorbance measurements. As little as ... fluorescence microplate readers and fluorometers using ...
... serum is extensively scrutinized, including ... All horses are of ... worming are controlled and documented ... consistency. Pricing: $12/unit ...
Biology Products: